Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

Provided By GlobeNewswire

Last update: Feb 12, 2025

CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2024 financial results after the market close on Wednesday, February 26, 2025.

CPRX Latest News and Analysis

10 days ago - ChartmillWhy NASDAQ:CPRX qualifies as a high growth stock.

A fundamental analysis of (NASDAQ:CPRX): Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s Growth Prospects.

11 days ago - ChartmillInvestors should take note of NASDAQ:CPRX, a growth stock that remains attractively priced.

Based on Fundamental Analysis it can be said that NASDAQ:CPRX is a growth stock which is not overvalued.

12 days ago - ChartmillUnlocking the Growth Potential of NASDAQ:CPRX.

A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.

13 days ago - ChartmillExploring NASDAQ:CPRX's high growth characteristics.

CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for high growth investors. Here's why. Full fundamental and technical analysis of (NASDAQ:CPRX).

16 days ago - ChartmillWhy NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation.

Based on a technical and fundamental analysis of NASDAQ:CPRX we can say: CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout.

18 days ago - ChartmillNASDAQ:CPRX: good value for what you're paying.

Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation.

Follow ChartMill for more